Press Releases

The latest press releases from bridge therapeutics

07/10/18 Pharma Startup, Bridge Therapeutics, Will Unveil Its Chronic Pain Drug Development Program at the 2018 Young Startup Ventures Summit in New York

Executives with the innovative late development-stage pharmaceutical startup, Bridge Therapeutics, announced they would showcase their chronic pain drug development program to venture capitalists at the 2018 Young Startup Ventures Summit in New York.

July 9th 2018

More than 150 venture capitalists will hear pitches and programs from various companies and startups in fields ranging from fintech to life sciences. The 2018 New York Venture Summit will take place at Convene in New York on July 10-11. Tim Peara said this forum would enable venture capitalist to hear how Bridge’s work towards developing a safer alternative for chronic pain has been progressing.

Read More

05/16/18 Pharmaceutical Startup, Bridge Therapeutics, Announces New Headquarters in Birmingham, Alabama

Bridge Therapeutics has announced they will be expanding their operations into one of the finest locations in Birmingham, Alabama. The new headquarters at the Summit in Birmingham is currently under design by the award-winning architectural firm Chambless King Architects.

May 16, 2018

“Our new headquarters will bring a new energy to Bridge Therapeutics,” said Alton Kelley, Director of Business Development. “We are all excited about this next step. We hope our new headquarters will attract other businesses to the Birmingham area, and ignite new economic growth in our community.”

John Chambless, the lead architect behind the new office design, said he wanted the new space to convey a sense of growth and change to investors and partners who visit there.

Read the full article here

 

03/14/18 Pharmaceutical Startup, Bridge Therapeutics, Announces Tim Peara Will Be Joining the Company as the Director of Finance

The innovative late development-stage pharmaceutical startup, Bridge Therapeutics has announced Tim Peara will be joining its management team as the new Director of Finance, effective immediately.

March 14, 2018

Tim Peara has more than 30 years of experience with institutional investments and technology start-ups. He has negotiated and structured investments, conducted due diligence, and built financial models for companies in finance, energy tech, and industry. Mr. Peara has also built and led teams while consulting to a variety of businesses.

Tim holds a BA in Latin American Studies from Wesleyan University in Connecticut and an MBA in Finance & International Business from the University of Chicago’s Booth School of Business.

Read More

02/21/18 Pharmaceutical Startup, Bridge Therapeutics, Names David H. Bergstrom, Ph.D. as New Chief Operating Officer

The innovative late development-stage pharmaceutical startup, Bridge Therapeutics, has named David H. Bergstrom, Ph.D. as its new Chief Operating Officer effective immediately.

February 21, 2018

Dr. Bergstrom has more than 30 years of new product development and commercialization experience in the pharmaceutical industry. He has overseen and been intimately involved in moving new products from the research phase to eventual successful commercial production. He has also launched products across numerous therapeutic areas and dosage form delivery technologies.

Dr. Bergstrom earned his Ph.D., M.S. and B.S. degrees in Pharmaceutics, Pharmaceutical Chemistry and Pharmacy from the University of Utah, The University of Michigan and Ferris State University, respectively.

Read More

05/19/17 Bridge Therapeutics to Present at BioTrinity 2017 Conference in London

CEO Dr. Greg Sullivan to introduce Bridge and its investigational drug BT-205 to investors and industry executives

May 10, 2017

(PRNewswire) — Bridge Therapeutics, Inc., an innovative development-stage specialty pharmaceutical company, announced that its CEO and Chief Scientific Officer Greg Sullivan, MD, presented at BioTrinity 2017 in London on Thursday, May 11. BioTrinity is Europe’s leading biopartnering and investment conference and the largest of its type in the UK. The conference, in its 11th year, draws attendees from approximately 30 countries and includes more than 1,000 delegates, dozens of exhibitors, and industry leaders from investment firms and global pharma.

Dr. Sullivan’s presentation to key investors and senior industry executives focused on the story of Bridge Therapeutics and its investigational drug compound BT-205, a unique combination of two synergistic chronic pain drugs—the partial-agonist opioid buprenorphine and the NSAID meloxicam—delivered in a state-of-the-art sublingual formulation.

Read more

For more information about Bridge Therapeutics please contact us today using the form below.